Molecular Profiling in Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-03

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol is to obtain tumor tissues and blood samples from patients with a confirmed histological diagnosis of Small cell lung cancer(SCLC) for molecular profiling.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment

NCT06086587

Lung Cancer

NOT_YET_RECRUITING

LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer

NCT06778512

Lung Lung Cancer Cancer +1 more

RECRUITING

Prospective Screening Programme for Malignant Tumors

NCT04230200

Hematologic Tests Malignant Tumor

UNKNOWN

Integrative Analysis of Large-cell Lung Cancer

NCT02917369

Lung Cancer

RECRUITING

Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China

NCT01928836

Lung Neoplasms

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Small cell lung cancer (SCLC) is most invasive subtypes of lung cancer. After diagnosis, the SCLC patients without treatment often die in 2-4 months. SCLC is a highly heterogeneous malignant tumor, the previous treatment principle of the tumor is based on the traditional histopathology, which not provide accurate guidance for precise treatment. In recent years, breakthrough has been made in molecular classification of breast cancer, non-small cell lung cancer, gastrointestinal cancer and of the other tumor, but SCLC molecular classification has not yet reported.

In this prospective study, SCLC tissues and blood samples from extensive SCLC patients will be obtained and evaluated of molecular profiling. Eligible population includes: patients who have not undergone any treatment and diagnosed of extensive SCLC by immunohistochemistry(IHC). The purpose is to evaluate molecular profiling of SCLC patients who are sensitive or resistant to chemotherapy (Cisplatin+Etoposide). To compare molecular alterations of SCLC patients with different prognosis (Overall Survival, Progress Free Survival).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: between 18 and 75 years old.
* Sexes Eligible for Study: All
* Diagnosed of SCLC by IHC, and divided into extensive stage.
* The ECOG (Eastern Cooperative Oncology Group, ECOG) PS(performance status，PS) Scale score is 0 or 1.
* At least one measurable lesions by CT scan.
* Expect to survive for at least three months.
* Peripheral blood routine and liver and kidney function meet the following criterion (blood draw 7 days before the treatment begins) :
* The White Blood Cell (WBC) is greater than the 3.0×10\^9/L or neutrophils (ANC) more than 1.5 x10\^9/L;
* Hemoglobin (HGB) is greater than 80 g/L.
* Platelet (PLT) is greater than 100×10\^9/L.
* (AST/ALT): Aspartate aminotransferase/Alanine aminotransferase\<3.0 times of normal range.
* Total bilirubin (TBIL) \< 1.5 times of normal range.
* Creatinine (CREAT) \< 1.5 times of normal range.
* Female or male patients must adopt effective birth control measures.
* Informed consent forms provided. Patients must meet each of the above criteria.

Exclusion Criteria

* Other pathological types of tumors ,rather than small cell lung cancer.
* Incorporating other tumors in the early diagnosis;
* Patients who have received chemotherapy, radiotherapy or any other anti-cancer treatment.
* Patients that known to be allergic to the drug components involved in the study;
* Patients with severe allergies or allergies;
* Pregnant or breastfeeding women;
* Patients with acute infection which is difficult to control;
* Drug abuse, substance abuse, long-term alcohol and AIDS(Acquired Immune Deficiency Syndrome) patients.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No